Just Released: "Pipeline and Commercial Insight: Parkinson's Disease"

Recently published research from Datamonitor, "Pipeline and Commercial Insight: Parkinson's Disease - Reformulations sustain market growth in the absence of therapeutic breakthroughs", is now available at Fast Market Research
 
March 16, 2011 - PRLog -- In 2009, the Parkinson's disease market generated $2.2bn across the seven major markets. As the market approaches maturity, Datamonitor forecasts the growth to slow from a compound annual growth rate of 7.9% (2005-09) to 2.2% (2009-19), as pipeline entries partially offset the generic erosion of key brand sales.
Features and benefits

* Quantify the historic (2005-09) and future (2010-19) size of the Parkinson's disease market.
* Comprehensive epidemiology review of the Parkinson's disease market authored by trained epidemiologists.
* Review of the current Parkinson's disease drug dynamics, including detailed profiles.
* Commercial and clinical assessment of key late-stage pipeline drugs, with key opinion leader comment and region-specific sales forecasts to 2019.
* Analysis of current treatment approaches, patient acquisition and clinical unmet needs.

Highlights

The major Parkinson's disease growth driver over the 2005-09 period was the dopamine agonist class, which accounted for nearly half the Parkinson's disease market sales, supported by the continued uptake of the newer catechol-O-methyltransferase (COMT) inhibitor and monoamine oxidase inhibitor (MAOI) classes.Parkinson's disease market growth is set to slump, as an unimpressive late-stage pipeline will fail to offset generic incursion. The US market will experience a considerable drop in market share, from 32% in 2009 to 25% in 2019, as generics take hold.New reformulations and the novel adenosine A2a receptor antagonist drugs do not offer the benefits or differentiation required to usurp traditional therapies.
Your key questions answered

* What are the commercial prospects of current and potential therapies for Parkinson's disease over the next 10 years?
* How will the impact of recent patent expiries and new product launches affect the Parkinson's disease market?
* How receptive is the market to new pipeline drugs and reformulations, in light of the availability of generic dopamine agonists?
* How will the new class of adenosine A2a receptior antagonists perform in the future marketplace?
* What are the current treatment approaches and unmet medical needs in Parkinson's disease?


For more information or to purchase this report, go to:
-  http://www.fastmr.com/prod/109705_pipeline_and_commercial...


Partial Table of Contents:

Executive Summary
Strategic scoping and focus
Datamonitor insight into the disease market
Related reports
VERVIEW
Catalyst
Summary
1. PATIENT POTENTIAL
Key findings
Market definition for Parkinson's disease
Disease definition
Unmet needs in Parkinson's disease
Disease-modifying therapy
Efficacy in reducing motor complications
Reduced non-motor side effects
Reduced pill burden
Delayed introduction of levodopa therapy
2. EPIDEMIOLOGY
Key findings
Introduction
Disease definition and diagnosis criteria
Global variation and temporal trends
Prevalence: stable across markets
Incidence: stable in time
Survival: improved by treatment
Mortality: decreased in the young
Comorbidities of Parkinson's disease
Risk factors
Age: strongest risk factor
Gender: more prevalent in males
Genetic predisposition: strong in patients under 50
Lifestyle factors: role of smoking and diet
ther factors: agricultural chemicals are strong predictors
Epidemiologic forecasting of Parkinson's disease
Sources of epidemiologic data: door-to-door studies
Description of methods
US
Japan
European markets
Results
Current prevalent cases and future trends
Discussion
Strengths and limits of Datamonitor's epidemiologic projections
Conclusions
3. MARKET OVERVIEW
Key findings
Market definition for this report
Seven major markets
Current and future market overview
The Japan and the five major European markets are expected to drive growth
Newer classes drove historical growth
Generics to stifle long-term growth
Undifferentiated pipeline therapies will struggle to compete with existing brands and generics
US
Current and future market overview
Japan
Current and future market overview
Five major EU markets
Current and future market overview
France
Current and future market assessment
Germany
Current and future market assessment
Italy
Current and future market assessment
Spain
Current and future market assessment
UK
Current and future market assessment
Rest of the world snapshot
Current market assessment
Rest of the world accounts for a third of Parkinson's disease prescription by volume
Patient acquisition process
Introduction
Trigger point 1: dopaminergics
Trigger point 2: dopamine agonists
Trigger point 3: catechol-O-methyltransferase inhibitors
Trigger point 4: monoamine oxidase inhibitors
ther treatments
4. BRAND DYNAMICS
Key findings
verview of competitive landscape
Current brand dynamics
Generic entry will cause market leaders to lose status during the forecast period
Drivers of brand choice
Ability to control motor symptoms
Cost
Side-effect profile
Patient convenience
Potential neuroprotective properties
US formulary tier status for leading brands
Mirapex and Mirapex ER (pramipexole; Boehringer Ingelheim)
Drug overview
Drug profile
Product positioning
Dopamine agonists move from adjunctive to first-line therapy
SWOT analysis for Parkinson's disease
Brand forecast to 2019
Requip and Requip XL (ropinirole; GlaxoSmithKline)
Drug overview
Drug profile
Product positioning

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=1097...

About Datamonitor

The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment.  View more research from Datamonitor at http://www.fastmr.com/catalog/publishers.aspx?pubid=1002

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

# # #

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
End
Source: » Follow
Email:***@fastmr.com Email Verified
Zip:01267
Tags:Drug, Disease, Pipeline, Parkinson, Clinical, Trial, Journals, Agonist, Compound, Early Stage
Industry:Medical, Research, Biotech
Location:Massachusetts - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Fast Market Research News
Trending
Most Viewed
Daily News



Like PRLog?
9K2K1K
Click to Share